New drug for common virus passes first safety check in healthy volunteers
NCT ID NCT06444048
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 26 times
Summary
This early-stage study tested the safety of a single dose of an experimental drug called EV68-228-N in 36 healthy adults aged 18 to 49. Participants received either the drug or a placebo by IV, and were monitored for side effects for up to 29 days. The goal was not to treat illness, but to gather safety information needed before testing the drug in people with enterovirus infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENTEROVIRUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0011, United States
Conditions
Explore the condition pages connected to this study.